“Lay's potato chips can contain acrylamide, a chemical that forms naturally when starchy foods like potatoes are fried at high temperatures." SECONDARY CLAIM (on-image text, same post): "LAY'S POTATO CHIPS FOUND TO CONTAIN EXCESSIVE AMOUNTS OF TOXINS LINKED TO PROMOTION OF TUMOR GROWTH, CANCER, ORGAN TOXICITY, AND NEUROTOXICITY - AND,…”

On formation and presence. The FDA states directly that acrylamide is a chemical that can form in some plant-based foods during high-temperature cooking such as frying, roasting and baking, forming primarily in cooked plant-based foods including potato products such as French fries and potato chips. The mechanism is specified: acrylamide forms in foods from a chemical reaction between asparagine (an amino acid) and reducing sugars (such as glucose and fructose). FDA guidance repeats that acrylamide formation occurs primarily in plant-based foods, notably potato products such as french fries and potato chips, cereal-grain-based foods, and coffee, and that acrylamide is also found in cigarette smoke and is produced industrially for use in products such as plastics, grouts, water treatment products, and cosmetics. Lay's products specifically appear by name in acrylamide testing. FDA's exploratory survey data on named retail products was summarized by CSPI in product charts sourced to U.S. FDA Exploratory Data on Acrylamide in Foods, which list named potato chip and crisp products including a Lay's product, alongside figures such as Pringles Sweet Mesquite BBQ Flavored Potato Crisps at 2510 ppb and Pringles Ridges Original Potato Crisps at 1286 ppb. More recently, Consumer Reports tested packaged children's snacks and found Nature Valley Crunchy Granola Bars had the highest reported level at 10.1 micrograms per 42-gram serving, followed by Lay's Classic Potato Chips at 7.37 micrograms per 28-gram serving and Snyder's Mini Pretzels at 4.48 micrograms per 28-gram serving. In that assignment, 14 of 21 popular packaged children's snacks contained at least one contaminant at levels CR considered concerning, while heavy metal levels were generally low and seven products had no contaminants above CR's levels of concern. On carcinogenicity. IARC placed acrylamide in Group 2A, and its own summary is explicit about the evidence split: there is inadequate evidence in humans for the carcinogenicity of acrylamide, and sufficient evidence in experimental animals. The classification rested on positive bioassay results in mice and rats, supported by evidence that acrylamide is biotransformed in mammalian tissues to a chemically reactive genotoxic metabolite, namely glycidamide. In occupational cohort studies of exposed workers, no consistent effect of acrylamide exposure on cancer incidence at any site was identified. EFSA's 2015 opinion reconfirmed concern on the basis of animal data: evidence from animal studies shows that acrylamide and its metabolite glycidamide are genotoxic and carcinogenic, damaging DNA and causing cancer, while acknowledging that evidence from human studies remained limited. EFSA's formal conclusion states that although the epidemiological associations have not demonstrated acrylamide to be a human carcinogen, the margins of exposure indicate a concern for neoplastic effects. On organ toxicity and neurotoxicity. EFSA identified neurotoxicity, adverse effects on male reproduction, developmental toxicity and carcinogenicity as possible critical endpoints for acrylamide toxicity from experimental animal studies, with data from human studies inadequate for dose-response assessment, and selected a BMDL10 of 0.43 mg/kg body weight per day for peripheral neuropathy in rats and 0.17 mg/kg body weight per day for neoplastic effects in mice. Critically for this claim, the Panel concluded that the current levels of dietary exposure to acrylamide are not of concern with respect to non-neoplastic effects, and in the draft stage EFSA similarly considered nervous system, developmental and male reproductive effects and concluded that based on current levels of dietary exposure this was not considered a concern. Human acrylamide neurotoxicity is real but is an occupational phenomenon: most cases of human acrylamide toxicity have occurred in the context of chronic occupational exposure, with predominant routes believed to be combined inhalational and dermal, and in workers subchronic exposure causes neuropathies, numbness of hands and feet, gait abnormalities, muscle weakness and ataxia. The relevant dietary comparison is that mean and 95th percentile dietary acrylamide exposures across surveys and age groups were estimated at 0.4 to 1.9 micrograms per kilogram body weight per day and 0.6 to 3.4 micrograms per kilogram body weight per day respectively, roughly two to three orders of magnitude below the rat neuropathy benchmark dose. On "excessive" and on mitigation. There is no binding US limit. FDA's document is non-binding guidance under which FDA recommends companies be aware of the levels of acrylamide in the foods they produce and intends only to suggest possible approaches to reducing acrylamide. The EU sets indicative benchmarks rather than legal maxima: Regulation 2017/2158 reports reference levels of 500 micrograms per kilogram in French fries and 750 micrograms per kilogram in other potato snacks including crisps, and for crisps the first indicative value was 1000 micrograms per kilogram, subsequently revised down to 750. Exceedances across the category are common: in Spain acrylamide in crisps ranged from 160 to 2871 micrograms per kilogram in 2025, half of samples exceeded the 750 benchmark, and levels increased in 2025, reversing a previous downward trend; an earlier Spanish survey found average content in 2019 of 664 micrograms per kilogram, 55.3 percent lower than 2004, with 27 percent of samples above the benchmark. Mitigation is technically established: FDA advises that lowering temperature and cooking to a lighter color may help lower acrylamide levels in potato chips and that its Acrylamide in Foods Guidance provides information to help growers, manufacturers, and food service operators reduce acrylamide levels. Europe-wide, mean acrylamide in potato crisps fell from 763 micrograms per kilogram in 2002 to 358 in 2011, a 53 percent decrease, with a 2016 update putting the mean at 412. On Frito-Lay specifically. California sued under Proposition 65 and settled. Heinz, Frito-Lay, Kettle Foods and Lance agreed to reduce levels of acrylamide in their potato chips and french fries as part of a settlement with the California Attorney General, after the state sued the companies in 2005 along with Burger King, Wendy's, McDonald's, KFC and Procter & Gamble. The operative term: the company agreed to post warning labels on, or stop selling, any chips that exceed 275 parts per billion, and Frito-Lay agreed to pay 1.5 million dollars in penalties and costs. Separately, Procter & Gamble agreed in January of that year to reduce acrylamide by 50 percent in Pringles potato chips.